Pattern of activin A and follistatin release in a sheep model of cardiopulmonary bypass

Cytokine

Volumn 54, Issue 2, 2011, Pages 154-160

  Chen, Yi ^a   Phillips, David J ^a   McMillan, James ^a   Bedford, Penny ^a   Goldstein, Jacob ^a   Wu, Hui ^a   Hedger, Mark P ^a   Smith, Julian A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Activin A; Cardiopulmonary bypass; Follistatin; Inflammation

Indexed keywords

ACTIVIN A; FOLLISTATIN; HEPARIN; INTERLEUKIN 6; LEPIRUDIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE RELEASE; ISOLATION PROCEDURE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SURGICAL INJURY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THORACOTOMY;

ACTIVINS; ANIMALS; CASE-CONTROL STUDIES; CORONARY ARTERY BYPASS; FOLLISTATIN; INTERLEUKIN-6; MODELS, ANIMAL; SHEEP; TUMOR NECROSIS FACTOR-ALPHA;

OVIS ARIES;

EID: 79953062128     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.01.001     Document Type: Article

References (29)

1. Hall R.I., Smith M.S., Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg 1997, 85:766-782.
2. Larmann J., Theilmeier G. Inflammatory response to cardiac surgery: cardiopulmonary bypass versus non-cardiopulmonary bypass surgery. Best Pract Res Clin Anaesthesiol 2004, 18:425-438.
3. McBride W.T., Armstrong M.A., Crockard A.D., McMurray T.J., Rea J.M. Cytokine balance and immunosuppressive changes at cardiac surgery: contrasting response between patients and isolated CPB circuits. Br J Anaesth 1995, 75:724-733.
4. Schwartz J.D., Shamamian P., Schwartz D.S., Grossi E.A., Jacobs C.E., Steiner F., et al. Cardiopulmonary bypass primes polymorphonuclear leukocytes. J Surg Res 1998, 75:177-182.
5. Jones K.L., Mansell A., Patella S., Scott B.J., Hedger M.P., de Kretser D.M., et al. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci USA 2007, 104:16239-16244.
6. Phillips D.J., de Kretser D.M., Hedger M.P. Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev 2009, 20:153-164.
7. Jones K.L., de Kretser D.M., Clarke I.J., Scheerlinck J.P.Y., Phillips D.J. Characterisation of the rapid release of activin A following acute lipopolysaccharide challenge in the ewe. J Endocrinol 2004, 182:69-80.
8. Sidis Y., Mukherjee A., Keutmann H., Delbaere A., Sadatsuki M., Schneyer A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology 2006, 147:3586-3597.
9. Lerch T.F., Shimasaki S., Woodruff T.K., Jardetzky T.S. Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions. J Biol Chem 2007, 282:15930-15939.
10. Dybdahl B., Slordahl S.A., Waage A., Kierulf P., Espevik T., Sundan A. Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction. Heart 2005, 91:299-304.
11. Suda K., Kitagawa Y., Ozawa S., Saikawa Y., Ueda M., Abraham E., et al. Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: a predictor of clinical course after surgery?. Dis Esophagus 2006, 19:5-9.
12. Szerafin T., Hoetzenecker K., Hacker S., Horvath A., Pollreisz A., Arpad P., et al. Heat shock proteins 27, 60, 70, 90 alpha, and 20S proteasome in on-pump versus off-pump coronary artery bypass graft patients. Ann Thorac Surg 2008, 85:80-88.
13. Smith C., Yndestad A., Halvorsen B., Ueland T., Waehre T., Otterdal K., et al. Potential anti-inflammatory role of activin A in acute coronary syndromes. J Am Coll Cardiol 2004, 44:369-375.
14. Yndestad A., Ueland T., Oie E., Florholmen G., Halvorsen B., Attramadal H., et al. Elevated levels of activin A in heart failure - potential role in myocardial remodeling. Circulation 2004, 109:1379-1385.
15. Oshima Y., Ouchi N., Shimano M., Pimentel D.R., Papanicolaou K.N., Panse K.D., et al. Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury. Circulation 2009, 120:1606-1615.
16. Phillips D.J., Jones K.L., McGaw D.J., Groome N.P., Smolich J.J., Parsson H., et al. Release of activin and follistatin during cardiovascular procedures is largely due to heparin administration. J Clin Endocrinol Metab 2000, 85:2411-2415.
17. Jones K.L., de Kretser D.M., Phillips D.J. Effect of heparin administration to sheep on the release profiles of circulating activin A and follistatin. J Endocrinol 2004, 181:307-314.
18. FG Noera.G., Medici A.I., Gatti M.A. Cardiopulmonary bypass technique in sheep. Perfusion 1989, 4:291-296.
19. Murphy G.S., Marymont J.H. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2007, 21:113-126.
20. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003, 33:173-183.
21. Roth-Isigkeit A., Borstel T.V., Seyfarth M., Schmucker P. Perioperative serum levels of tumour-necrosis-factor alpha (TNF-alpha), IL-1 beta, IL-6, IL-10 and soluble IL-2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution. Clin Exp Immunol 1999, 118:242-246.
22. Knight P.G., Muttukrishna S., Groome N.P. Development and application of a two-site enzyme immunoassay for the determination of 'total' activin-A concentrations in serum and follicular fluid. J Endocrinol 1996, 148:267-279.
23. Klein R., Robertson D.M., Shukovski L., Findlay J.K., de Kretser D.M. The radioimmunoassay of follicle-stimulating hormone (FSH)-suppressing protein (FSP): stimulation of bovine granulosa cell FSP secretion by FSH. Endocrinology 1991, 128:1048-1056.
24. Jones K.L., Brauman J.N., Groome N.P., de Kretser D.M., Phillips D.J. Activin A release into the circulation is an early event in systemic inflammation and precedes the release of follistatin. Endocrinology 2000, 141:1905-1908.
25. Phillips D.J., Hedger M.P., McFarlane J.R., Klein R., Clarke I.J., Tilbrook A.J., et al. Follistatin concentrations in male sheep increase following sham castration/castration or injection of interleukin-1 beta. J Endocrinol 1996, 151:119-124.
26. Borgermann J., Scheubel R.J., Simm A., Silber R.E., Friedrich I. Inflammatory response in on-versus off-pump myocardial revascularization: is ECC really the culprit?. Thorac Cardiovasc Surg 2007, 55:473-480.
27. Ogawa K., Funaba M., Chen Y., Tsujimoto M. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J Immunol 2006, 177:6787-6794.
28. Sablotzki A., Welters I., Lehmann N., Menges T., Gorlach G., Dehne M., et al. Plasma levels of immunoinhibitory cytokines interleukin-10 and transforming growth factor-beta in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg 1997, 11:763-768.
29. Wan S., DeSmet J.M., Barvais L., Goldstein M., Vincent J.L., LeClerc J.L. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996, 112:806-811.